Results 241 to 250 of about 583,933 (296)
Some of the next articles are maybe not open access.
2013
Despite recent advances in the diagnosis and management of ischemic heart disease, it still remains a major cause of morbidity and mortality worldwide and thus warrants continuous challenges in therapeutics and research on its pathogenesis. It is widely accepted that ischemic heart disease is caused not only by plaque rupture and/or anatomical ...
Roberta L. Hines, Katherine E. Marschall
+8 more sources
Despite recent advances in the diagnosis and management of ischemic heart disease, it still remains a major cause of morbidity and mortality worldwide and thus warrants continuous challenges in therapeutics and research on its pathogenesis. It is widely accepted that ischemic heart disease is caused not only by plaque rupture and/or anatomical ...
Roberta L. Hines, Katherine E. Marschall
+8 more sources
Anesthesiology Clinics of North America, 2006
Because of changing demographics, increasing numbers of patients with IHD are presenting for noncardiac surgery, and the risks of perioperative morbidity and mortality are significant. The Lee Cardiac Risk Index is applicable in defining perioperative cardiac risk: however, ACC/AHA guidelines may not be applicable comprehensively.
Sanjeev Wasson, Lokesh Tejwani
openaire +3 more sources
Because of changing demographics, increasing numbers of patients with IHD are presenting for noncardiac surgery, and the risks of perioperative morbidity and mortality are significant. The Lee Cardiac Risk Index is applicable in defining perioperative cardiac risk: however, ACC/AHA guidelines may not be applicable comprehensively.
Sanjeev Wasson, Lokesh Tejwani
openaire +3 more sources
Annals of Internal Medicine, 2019
Stable ischemic heart disease (SIHD) is a leading cause of death in the United States and many other countries. The defining pathobiology is an imbalance between the metabolic demands of the myocardium and its oxygen supply, which most often results from coronary artery atherosclerosis.
Daniel, Katz, Michael C, Gavin
openaire +4 more sources
Stable ischemic heart disease (SIHD) is a leading cause of death in the United States and many other countries. The defining pathobiology is an imbalance between the metabolic demands of the myocardium and its oxygen supply, which most often results from coronary artery atherosclerosis.
Daniel, Katz, Michael C, Gavin
openaire +4 more sources
Ischemic Heart Disease: An Update
Seminars in Nuclear Medicine, 2020Ischemic heart disease is a dynamic process of atherosclerosis of the coronary arteries or functional alterations of coronary circulation that can be modified by lifestyle, pharmacological therapies, and revascularization. Such treatment may result in disease stabilization or regression.
Jensen, Rebekka Vibjerg +2 more
openaire +3 more sources
Heart Failure Clinics, 2014
Classical angina refers to typical substernal discomfort triggered by effort or emotions, relieved with rest or nitroglycerin. The well-accepted pathogenesis is an imbalance between oxygen supply and demand. Goals in therapy are improvement in quality of life by limiting the number and severity of attacks, protection against future lethal events, and ...
Richard, Kones, Umme, Rumana
openaire +3 more sources
Classical angina refers to typical substernal discomfort triggered by effort or emotions, relieved with rest or nitroglycerin. The well-accepted pathogenesis is an imbalance between oxygen supply and demand. Goals in therapy are improvement in quality of life by limiting the number and severity of attacks, protection against future lethal events, and ...
Richard, Kones, Umme, Rumana
openaire +3 more sources
American Heart Journal, 2000
The recent clinical development of drugs for acute ischemic heart disease provides examples of successes and failures in Phase II trials. In the development of thrombolytic therapy for acute myocardial infarction (MI), Phase II trials have generally been designed to identify approaches that improve myocardial reperfusion while minimizing the risk of ...
C B, Granger, A, Skene
openaire +2 more sources
The recent clinical development of drugs for acute ischemic heart disease provides examples of successes and failures in Phase II trials. In the development of thrombolytic therapy for acute myocardial infarction (MI), Phase II trials have generally been designed to identify approaches that improve myocardial reperfusion while minimizing the risk of ...
C B, Granger, A, Skene
openaire +2 more sources
Chronic ischemic heart disease
American Heart Journal, 2000Many advances have been made ln the medical therapy of chronicSischemlc heart disease. However, this disease remains the leading cause of death and disability, and, looking into the next millennium,1 researchers expect that it will continue in this position for the foreseeable future.
M, Gent, R M, Califf
openaire +2 more sources
Ischemic Heart Disease and Heart Weight
Cardiology, 1983Separate weights for heart ventricle walls and interventricular septa were analyzed in 110 hearts with autopsy findings of ischemic heart disease (coronary atherosclerosis, recent or old myocardial infarcts) and with no other cardiac or systemic causes of cardiac enlargement.
T, Romppanen, A, Seppä, H, Roilas
openaire +2 more sources